期刊文献+

激素联合不同免疫抑制剂治疗原发性IgA肾病的疗效及安全性 被引量:18

下载PDF
导出
摘要 目的:探讨激素联合不同免疫抑制剂对原发性IgA肾病伴轻中度肾功能受损患者的疗效及安全性。方法:选取符合原发性IgA肾病伴轻中度肾功能受损患者160例,采用完全随机化分组分为治疗一组、治疗二组、治疗三组及对照组,每组40例,均给予基础治疗,在此基础上治疗一组给予糖皮质激素治疗,治疗二组给予糖皮质激素联合来氟米特治疗,治疗三组给予糖皮质激素联合环磷酰胺治疗。治疗4、12周后检测各组患者的尿蛋白含量、血浆白蛋白及血肌酐的变化,并记录各组并发症的发生情况。结果:3个治疗组总有效率分别为82.5%、90.0%和75.5%,较对照组有效率(22.5%)显著提升(P<0.05);3个治疗组在尿蛋白明显下降的同时血浆白蛋白均得到提升,治疗12周后治疗二组患者提升效果最为明显。治疗4周后各治疗组患者血肌酐水平均出现降低;治疗12周后,各治疗组血肌酐水平进一步下降,其中治疗一组效果较治疗二、三组效果显著。治疗组无严重并发症发生。结论:采用激素治疗原发性IgA肾病可获得较好的治疗效果,并发症较少,患者预后良好;采取激素与免疫抑制剂联合的治疗方案患者无严重并发症出现,疗效较好,可以作为预选方案在临床使用。
出处 《实用医学杂志》 CAS 北大核心 2016年第10期1687-1689,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献10

  • 1刘丹,王彩丽.IgA肾病治疗进展[J].中外医疗,2014,33(32):189-191. 被引量:2
  • 2樊平,戴双明,邹川,刘旭生.IgA肾病的临床表现与病理特征研究[J].西安交通大学学报(医学版),2015,36(2):241-244. 被引量:25
  • 3LI M, FOO JN, WANG JQ, et al. Identification of new suscepti- bility loci for IgA nephropathy in Han Chinese [J]. Nat Com- mun, 2015,6:7270.
  • 4BERTHELOT L, ROBERT T, VUIBLET V, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, au- toantibodies and soluble CD89 complexes [J]. Kidney Int, 2015,88 (4) : 815-822.
  • 5SHEN H, GU W, MAO J, et al. Clinical characteristics of con- comitant nephrotic IgA nephropathy and minimal change disease in children [J ]. Nephron, 2015,130( 1 ) : 21-28.
  • 6邓武成,朱雪花,冉强,侯光强,张克波,廖华伟.IgA肾病预后的相关影响因素分析[J].现代生物医学进展,2013,13(34):6703-6706. 被引量:4
  • 7COPPO R, DAVIN JC. The difficulty in considering modifiable pathology risk factors in children with IgA nephropathy: cres- cents and timing of renal biopsy [J]. Pediatr Nephrol, 2015,30 (2) : 189-192.
  • 8王伟铭,贾晓媛,潘晓霞,沈平雁,刘剑,徐丽梨,李娅,王朝晖,李晓,任红,张文,陈楠.单纯激素、激素联合环磷酰胺和激素联合麦考酚酯治疗肾功能不全IgA肾病的临床研究[J].上海交通大学学报(医学版),2013,33(2):162-167. 被引量:19
  • 9SUZUKI H, SUZUKI Y, NOVAK J, et al. Development of ani- mal models of human igA nephropathy [J]. Drug Discov Today Dis Models, 2014,11:5-11.
  • 10CHEUNGPASITPORN W, NASR SH, THONGPRAYOON C, et al. Primary IgA nephropathy in elderly patients [J]. Nephrology (Carlton), 2015,20(6) :419-425.

二级参考文献73

  • 1刘刚,马序竹,邹万忠,王梅,王海燕.肾活检患者肾脏病构成十年对比分析[J].临床内科杂志,2004,21(12):834-838. 被引量:182
  • 2李占亭,杨洁,孙脊峰,杜德伟,刘丽丽,王莉.IgA肾病的治疗进展[J].第四军医大学学报,2007,28(10):952-953. 被引量:11
  • 3Li LS,Liu ZH. Epidemiologic data of renal diseases from a single unit in China:analysis based on 13 519 renal biopsies[J].Kidney International,2004,(03):920-923.
  • 4Zhou FD,Zhao MH,Zou WZ. The changing spectrum of primary glomerular diseases within 15 years:A survey of 3 331 patients in a single Chinese centre[J].Nephrology Dialysis Transplantation,2009,(03):870-876.
  • 5Lv J,Zhang H,Zhou Y. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis:a long-term follow up of 204 cases in China[J].Nephrology,2008,(03):242-246.doi:10.1111/j.1440-1797.2007.00898.x.
  • 6Kobayashi Y,Fujii K,Hiki Y. Steroid therapy in IgA nephropathy:a prospective pilot study in moderate proteinuric cases[J].Quarterly Journal of Medicine,1986,(234):935-943.
  • 7Lai KN,Lai FM,Ho CP. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome:a long-term controlled trial[J].Clinical Nephrology,1986,(04):174-180.
  • 8Pozzi C,Andrulli S,Del Vecchio L. Corticosteroid effectiveness in IgA nephropathy:long-term results of a randomized,controlled trial[J].Journal of the American Society of Nephrology,2004,(01):157-163.doi:10.1097/01.ASN.0000103869.08096.4F.
  • 9Cheng J,Zhang X,Zhang W. Efficacy and safety of glucocorticoids therapy for IgA nephropathy:a meta-analysis of randomized controlled trials[J].American Journal of Nephrology,2009,(04):315-322.
  • 10Ballardie FW Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy[J].Journal of the American Society of Nephrology,2002,(01):142-148.

共引文献46

同被引文献121

引证文献18

二级引证文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部